Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
 
Recent advances in SMANCS/Lipiodol therapy—enhanced targeting and delivery efficacy using vascular modulators
Akinori NagamitsuTakao InuzukaMichio KawasujiHiroshi Maeda
Author information
JOURNAL FREE ACCESS

2003 Volume 18 Issue 5 Pages 438-447

Details
Abstract
Recent advances in SMANCS/Lipiodol therapy for hepatic and other abdominal cancers are discussed. Two clinical procedural progresses described herein are arterial infusion of SMANCS/Lipiodol under angiotensin II induced hypertension (eg. 120 → 180 mmHg), which is followed by, or commitant infusion of SMANCS/Lipiodol and nitro-agent (nitroisosorbitol : nitrol®) i. a. via the catheter inserted at the femoral artery (Seldinger's method). SMANCS/Lipiodol is selectively deposited much higher extent by virtue of EPR-effect and this amount was increased 2∼4 fold under hypertensive condition followed by opening up the normal blood vessels by Nitrol® : This procedure also reduced side effect clinically to a great extent such as liver toxicity. X-ray CAT scan revealed much thickened uptake of SMANCS/Lipiodol in case of the metastatic liver cancer, cholangiocarcinoma, and pancreatic cancer, as well as hepatocellular carcinoma. For highly enhanced tumor selective delivery of SNIANCS/Lipiodol given i. a., the method using two vascular mediators (hypertension/systemic : vasodilatation/local) is more desirable than simple i. a. infusion, which resulted far better drug deposition and response, as well as QOL of the patients, than original SMANCS therapy under normotensive state.
Content from these authors
© Japan Society of Drug Delivery System
Previous article Next article
feedback
Top